Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/76419| Título: | P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy |
| Autor(es): | Cristelo, C. Gama, F. M. Sarmento, B. |
| Data: | 16-Jan-2022 |
| Citação: | Cristelo, C.; Gama, F. M.; Sarmento, B., Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy. XIV Spanish-Portuguese Conference on Controlled Drug Delivery (Virtual Meeting). No. P3.2, Tenerife, Spain, Jan 26-28, 145, 2022. |
| Resumo(s): | [Excerpt] Type 1 diabetes (T1D) is an autoimmune condition resulting in the destruction of the insulin-producing β cells. With no cure available for this disease, patients depend on insulin administration to control glycaemia. The recovery of β cells by promoting its replication, neogenesis or by reprogramming of other pancreatic cells, offers a promising strategy to revert T1D. |
| Tipo: | Resumo em ata de conferência |
| URI: | https://hdl.handle.net/1822/76419 |
| Versão da editora: | https://www.splc-crs.org/meeting-2022/ |
| Arbitragem científica: | yes |
| Acesso: | Acesso aberto |
| Aparece nas coleções: |
Ficheiros deste registo:
| Ficheiro | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| document_55343_1.pdf | 123,27 kB | Adobe PDF | Ver/Abrir |
